Last week Renewable Energy & Power, Inc. (OTC PINK : RBNW ), a diversified corporation with markets in energy-saving technologies of LED lighting, solar and wind energy, announced a large San Francisco Bay Area electronic assembly corporation has approved the installation of 1,275 LED lights for their entire main campus.
This is the third such announcement in as many months by the Las Vegas based company. It got me thinking about what the company does and how LED lighting can impact a business’ bottom line as much as it contributes to reducing emissions and the effects of global warming. But what about LED lights in RBNW’s backyard? How much of the Vegas Strip is LED? Well, it turns out, quite a bit.
Over a year ago three of Nevadas largest casino companies MGM Resorts, Wynn, and Las Vegas Sands announced plans to source renewable energy for their hotels, a move driven both by increasing demand for responsible energy use from the companies that rent their conference halls, and a surplus of cheap power from solar farms in Nevada and California. MGM Resorts had already implemented an ambitious energy conservation effort by replacing 1.3 million light bulbs in its properties with LEDs.
Top 10 Casino Stocks For 2018: CBOE Holdings Inc.(CBOE)
Advisors’ Opinion:
- [By David Zeiler]
Bats Global Markets was acquired on Feb. 28 by the Chicago Board Options Exchange (Nasdaq: CBOE).
But the Bats BZX Exchange has had a bigger role than just serving as the place where the Winklevoss ETF will be listed…
- [By David Zeiler]
Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.
- [By CNNMoney Staff]
Stocks continued to rally despite the fact that options trading was temporarily halted Monday afternoon at exchanges run by CBOE Holdings (CBOE), Nasdaq OMX (NDAQ), BATS Global Markets and Miami International Holdings due to issues at the Options Price Reporting Authority (OPRA), which provides trading data and price quotes.
- [By Wayne Duggan]
Wall Street has been watching bitcoin this week, with the price up another 39.8 percent to above $16,000 ahead of the highly anticipated launch of bitcoin futures trading by Cboe Global Markets Inc (NASDAQ: CBOE) starting Sunday. Bitcoin has been around for years, but bitcoin futures trading will make trading a breeze for average retail investors for the first time.
Top 10 Casino Stocks For 2018: TESARO, Inc.(TSRO)
Advisors’ Opinion:
- [By Todd Campbell]
The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).
- [By Todd Campbell]
Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.
- [By Ben Levisohn]
Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:
- [By Ben Levisohn]
Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:
Getty Images
We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).
We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…
Ex M&A,
- [By Ben Levisohn]
Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.
Agence France-Presse/Getty Images
The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:
AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.
The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).
Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.
In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?
Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.
UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:
This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth
Top 10 Casino Stocks For 2018: Valhi Inc.(VHI)
Advisors’ Opinion:
- [By Lisa Levin]
In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.
Top 10 Casino Stocks For 2018: ONEOK Inc.(OKE)
Advisors’ Opinion:
- [By Matthew DiLallo]
Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.
- [By Garrett Cook]
Citi maintains Buy ratings on Targa Resources (NYSE: TRGP), ONEOK (NYSE: OKE) and Oneok Partners (NYSE: OKS) citing the companies stories around natural gas liquids (NGLs).
Top 10 Casino Stocks For 2018: Gerdau S.A.(GGB)
Advisors’ Opinion:
- [By Manikandan Raman]
On the news, Freeport-McMoRan surged 12 percent to $10.20 and Lundin Mining climbed 12 percent to $3.33. Gerdau SA (ADR) (NYSE: GGB) rose 19 percent to $1.23, Vale SA (ADR) (NYSE: VALE) advanced 18 percent to $4.85 and Banco Bradesco SA (ADR) (NYSE: BBD) gained 11 percent to $7.15.
Top 10 Casino Stocks For 2018: Firsthand Technology Value Fund, Inc.(SVVC)
Advisors’ Opinion:
- [By Hibah Yousuf]
Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.
Top 10 Casino Stocks For 2018: URS Corporation(URS)
Advisors’ Opinion:
- [By Ben Levisohn]
Fidelty’s John Mirshekaritook a look at URS(URS) today at the Value Investing Congress.His takeaway: The stock could double in two years.
Agence France-Presse/Getty Images
His analysis started with URS’s use of its free cash. During the past, it hasn’t been pretty. They spent 6.3 billion on eight acquisitions, they’ve bought companies at valuations higher than own stock and return-on-equity has dropped from high teens to just 6%.
The problem hasn’t been its business: Its return on tangible capital is 17%. Instead, the problem is that its management hasn’t maximized value through capital allocation. URS has lowest valuation: 9x 2013 cash earnings in its industry.
Part of the problem: Management incentives are based on net income. This year, however, relative total shareholder return was added., something Mirshekari calls”a step in the right direction.” In May, URS filed an amended proxy which says it will look to change incentives from net income to return on equity and earnings per share. More importantly, it said acquisitions would end.
If all goes right, URS could double in two years,Mirshekari says, comparing it to AECOM Technology (ACM).
Looks a lot like AECOMM, which did something similar and rallied.
- [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]
Fund manager John Mirshekari, of the Fidelity Low-Priced Stock Fund, recommended shares of URS (URS), an engineering and construction contractor.
Top 10 Casino Stocks For 2018: LaSalle Hotel Properties(LHO)
Advisors’ Opinion:
- [By Marshall Hargrave]
The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.
Top 10 Casino Stocks For 2018: Reinsurance Group of America, Incorporated(RGA)
Advisors’ Opinion:
- [By Benzinga News Desk]
Morgan Stanley downgraded Chipotle (NYSE: CMG) to Equal-Weight.
UBS downgraded AMC Networks (NASDAQ: AMCX) to Sell.
Citi upgraded Sealed Air (NYSE: SEE) to Buy.
Goldman Sachs upgraded Reinsurance Group (NYSE: RGA) to Buy. - [By David Sterman]
My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).
Top 10 Casino Stocks For 2018: Portola Pharmaceuticals, Inc.(PTLA)
Advisors’ Opinion:
- [By Lisa Levin]
Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.
Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.
- [By Lisa Levin]
Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.
Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.
- [By Lisa Levin]
Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares were also up, gaining 46 percent to $55.68 after the company disclosed that the FDA has approved Bevyxxa, a blood-thinner for acutely ill patients not undergoing surgery. BevyxXa is the first oral drug of its kind to be approved to help prevent deep vein thrombosis and pulmonary embolisms..
- [By Todd Campbell]
Portola Pharmaceuticals’ (NASDAQ:PTLA)could have two commercial-stage drugs on the market next year, but turning them into top-sellers will require a lot of money. Is Portola Pharmaceuticals’ balance sheet flush enough with cash to get its drugs across the finish line?
